Literature DB >> 25580186

Clinical Monitoring of Chronic Hepatitis C Based on its Natural History and Therapy.

Douglas L Nguyen1, Ke-Qin Hu1.   

Abstract

Hepatitis C virus (HCV) infection is a major public health problem and a leading cause of chronic liver disease. Chronic HCV infection often follows a progressive course over years and can result in cirrhosis, hepatocellular carcinoma, and need for liver transplantation. In the United States alone, the estimated prevalence of HCV infection is up to 5.1 million persons. The optimal approach to detecting HCV infection is to screen persons for possible history of risks of exposure to virus and to test those selected individuals with risk factors. Both host and viral factors may be important contributors to the natural history of HCV. Currently, effective pharmacologic therapy are available to induce sustained virologic response (SVR) or virologic "cure," which results in improved morbidity and mortality. Patient education before treatment is essential and should include a full discussion of potential side effects. It is important to work collaboratively and closely with patients to ensure early recognition of adverse events and to effectively manage them in order to ensure treatment compliance. This paper provides a thorough overview on screening for the diagnosis, clinical management, and treatment indications and contraindications for chronic hepatitis C.

Entities:  

Keywords:  Hepatitis C virus (HCV); chronic hepatitis C (CHC); chronic liver disease; cirrhosis; hepatitis C treatment

Year:  2014        PMID: 25580186      PMCID: PMC4287404     

Source DB:  PubMed          Journal:  N Am J Med Sci (Boston)        ISSN: 1946-9357


  79 in total

1.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Authors: 
Journal:  J Hepatol       Date:  2011-03-01       Impact factor: 25.083

2.  Host genetic factors influence disease progression in chronic hepatitis C.

Authors:  E E Powell; C J Edwards-Smith; J L Hay; A D Clouston; D H Crawford; C Shorthouse; D M Purdie; J R Jonsson
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

3.  Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease.

Authors:  M Asti; M Martinetti; C Zavaglia; M C Cuccia; L Gusberti; C Tinelli; A Cividini; S Bruno; L Salvaneschi; G Ideo; M U Mondelli; E M Silini
Journal:  Hepatology       Date:  1999-04       Impact factor: 17.425

4.  IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes.

Authors:  Pierre-Yves Bochud; Stéphanie Bibert; Zoltán Kutalik; Etienne Patin; Julien Guergnon; Bertrand Nalpas; Nicolas Goossens; Lorenz Kuske; Beat Müllhaupt; Tillman Gerlach; Markus H Heim; Darius Moradpour; Andreas Cerny; Raffaele Malinverni; Stephan Regenass; Guenter Dollenmaier; Hans Hirsch; Gladys Martinetti; Meri Gorgiewski; Marc Bourlière; Thierry Poynard; Ioannis Theodorou; Laurent Abel; Stanislas Pol; Jean-François Dufour; Francesco Negro
Journal:  Hepatology       Date:  2011-12-16       Impact factor: 17.425

Review 5.  Hepatitis C virus infection in USA: an estimate of true prevalence.

Authors:  Eric Chak; Andrew H Talal; Kenneth E Sherman; Eugene R Schiff; Sammy Saab
Journal:  Liver Int       Date:  2011-03-16       Impact factor: 5.828

6.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

Authors:  Laurent Castéra; Julien Vergniol; Juliette Foucher; Brigitte Le Bail; Elise Chanteloup; Maud Haaser; Monique Darriet; Patrice Couzigou; Victor De Lédinghen
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

7.  The long-term pathological evolution of chronic hepatitis C.

Authors:  M Yano; H Kumada; M Kage; K Ikeda; K Shimamatsu; O Inoue; E Hashimoto; J H Lefkowitch; J Ludwig; K Okuda
Journal:  Hepatology       Date:  1996-06       Impact factor: 17.425

Review 8.  Treatment of hepatitis C.

Authors:  J Heathcote; J Main
Journal:  J Viral Hepat       Date:  2005-05       Impact factor: 3.728

9.  Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C.

Authors:  F Pessione; F Degos; P Marcellin; V Duchatelle; C Njapoum; M Martinot-Peignoux; C Degott; D Valla; S Erlinger; B Rueff
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

10.  Clinical outcomes after transfusion-associated hepatitis C.

Authors:  M J Tong; N S el-Farra; A R Reikes; R L Co
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

View more
  4 in total

1.  Barriers to Treatment Among New York City Residents with Chronic Hepatitis C Virus Infection, 2014.

Authors:  Andrea King; Katherine Bornschlegel; Nirah Johnson; Eric Rude; Fabienne Laraque
Journal:  Public Health Rep       Date:  2016 May-Jun       Impact factor: 2.792

Review 2.  Hedgehog signalling in liver pathophysiology.

Authors:  Mariana Verdelho Machado; Anna Mae Diehl
Journal:  J Hepatol       Date:  2017-10-26       Impact factor: 25.083

3.  Hepatitis C virus antigens enzyme immunoassay for one-step diagnosis of hepatitis C virus coinfection in human immunodeficiency virus infected individuals.

Authors:  Ke-Qin Hu; Wei Cui; Susan D Rouster; Kenneth E Sherman
Journal:  World J Hepatol       Date:  2019-05-27

4.  Access to hepatitis C medicines.

Authors:  Danny J Edwards; Delphi Gm Coppens; Tara L Prasad; Laurien A Rook; Jayasree K Iyer
Journal:  Bull World Health Organ       Date:  2015-10-08       Impact factor: 9.408

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.